Form 4: CervoMed CEO's Spouse Granted 8,100 Stock Options as Non-Employee Director

John J. Alam, CEO and President of CervoMed Inc., reported an indirect acquisition of 8,100 stock options granted to his spouse, Sylvie Gregoire, a non-employee director, with an exercise price of $6.52 per share.

Summary

• John J. Alam, who serves as CEO, President, Director, and 10% Owner of CervoMed Inc. (CRVO), filed a Form 4 reporting an indirect beneficial ownership change.
• The filing details the grant of 8,100 stock options to Sylvie Gregoire, PharmD., who is the reporting person's spouse and a non-employee director of CervoMed Inc.
• The stock options have an exercise price of $6.52 per share.
• The transaction date for the option grant was June 23, 2025.
• The options become exercisable on June 23, 2025, and have an expiration date of June 23, 2035.
• The underlying securities are 8,100 shares of CervoMed Common Stock.
• The shares underlying the award will vest on a monthly basis over a one-year period, in substantially equal 1/12th increments, beginning on June 30, 2025.
• Vesting is contingent upon Dr. Gregoire's continued service through the applicable vesting date.
• John J. Alam disclaims beneficial ownership of these securities, and the report is not an admission of beneficial ownership for Section 16 purposes or any other purpose.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a standard compensation practice that aligns director interests with shareholders, indicating stability in governance and incentive structures. It is not highly impactful on its own.

Positives

• The grant of stock options to a non-employee director aligns her interests with those of the company's shareholders, incentivizing long-term value creation.
• Equity compensation is a standard practice for attracting and retaining qualified board members in the biotechnology sector.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, though this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is dependent on the future market price of CervoMed Inc. common stock, which is subject to market volatility.
• The vesting of the options is subject to Dr. Gregoire's continued service as a director, meaning the full benefit is not immediately realized.

Future Outlook

The stock options granted will vest monthly over a one-year period beginning June 30, 2025, subject to the director's continued service, indicating a future commitment and incentive structure for the coming year.

Management Comments

• John J. Alam, through his attorney-in-fact, disclaims beneficial ownership of the securities granted to his spouse, stating that the report should not be deemed an admission of beneficial ownership for Section 16 or any other purpose.

Industry Context

The grant of stock options to non-employee directors is a common and widely accepted practice in the biotechnology and pharmaceutical industries. It serves to align the interests of board members with those of shareholders, encouraging long-term strategic decisions that enhance company value.

Comparison to Industry Standards

• The granting of stock options as part of a non-employee director's compensation package is a standard industry practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While the document does not provide specific comparable companies or projects, the structure of the option grant, including the exercise price and vesting schedule, is consistent with typical equity compensation plans designed to incentivize long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The stock option grant to Sylvie Gregoire, PharmD., is a related party transaction as she is the spouse of John J. Alam, the CEO, President, Director, and 10% Owner of CervoMed Inc.

Stakeholder Impact

• Shareholders: Potential minor dilution from future option exercise, but also benefit from aligned interests of a director.
• Director (Sylvie Gregoire): Receives equity compensation, incentivizing her continued service and performance.
• Management (John J. Alam): Disclosure of spouse's compensation ensures transparency regarding related party dealings.

Next Steps

• The stock options will begin vesting on a monthly basis starting June 30, 2025, over a one-year period, contingent on Dr. Gregoire's continued service.

Key Dates

Keywords

CervoMed Inc., CRVO, SEC Form 4, Stock Options, Equity Compensation, Director Compensation, Insider Trading, Beneficial Ownership, Vesting Schedule, Biotechnology